Update - Zayed National Museum and Bahrain Launch Six-Week Archaeologica… Transport - Dubai RTA Introduces Five-Star Rating System for Taxi Companies… Weather - Rain Expected in Some Areas on November 16 as Temperatures Drop…

Send an Inquiry

Fill in the details below and our team will get back to you.

Healthcare 1 min read 80 views

Changes to gene therapy are successful and safer for children with immune disorder

Alterations to the delivery method, which are published in the New England Journal of Medicine, leads to a high success rate and the small risk of patients of developing complications, such as cancer, is reduced even further.

SCID is a condition in which children are born without an immune system because of a defect in the gene IL2RG. This condition is sometimes referred to as bubble baby disease in the media, because patients need to live in a sterile environment. Treatment for SCID usually involves patients receiving a bone marrow transplant in order to boost numbers of white blood cells but without a compatible bone marrow donor this can be unsuccessful. If a donor cant be found, some patients can now be given gene therapy where a faulty gene is replaced by a working gene, leading to their immune systems functioning at normal levels.

Gene therapy relies upon a vehicle, known as a vector that delivers the working gene in to the body and integrates it into a childs DNA. These vehicles are usually viruses which are good at inserting themselves in to peoples genetic material that are modified so the harmful aspects of the virus are removed. However, virus based vectors can sometimes cause problems and activate genes within the body in the wrong way, occasionally leading to leukaemia.

An international team of researchers have now tweaked the design of the most commonly used vector in order to try and remove this risk. After trialling the altered vector during gene therapy in nine boys with SCID, they found that it worked as efficiently as previous vectors in terms of correcting immune problems, and there have been no signs of side effects, including the development of leukaemia, in the three years since the therapy.

Adrian Thrasher, Professor of Paediatric Immunology at GOSH who led the research, says: While the long term effect on the development of cancer across the lifetime in these patients remains unknown, the changes that we have made to this vector appear hugely promising and suggest that we can now confidently address a much wider range of tractable disease targets through gene therapy.

The Immunology Unit at GOSH is recognised as a world leader in the diagnosis of suspected or confirmed primary immunodeficiency. We also have experience and expertise of treating a variety of other immunological disorders in children from all over the world.

Related News

More on Healthcare

View all

Comments (0)

Join the conversation

No comments yet. Be the first to share your thoughts!

More News

See all
Business

Big 5 Global 2026: Six French companies to showcase advanced construction technologies in Dubai

Six French companies will present their construction technologies and expertise at Big 5 Global 2026, scheduled to take place from November 23 to 26 at the Dubai World Trade Centre. Supported by Business France, AITENDERS, ALPHI ME, ARIADIS, COMUS, CSTB and QUADRA will showcase solutions across...

Nov 16, 2026 · 3 min
Education

JICE connects UAE students with higher education opportunities in Japan at NAJAH Abu Dhabi 2026

The Japan International Cooperation Center (JICE) welcomed approximately 1,200 visitors to the Japan Pavilion at NAJAH Abu Dhabi 2026, held from October 18 to 21 at ADNEC Centre Abu Dhabi. The initiative introduced students and families to higher education opportunities in Japan through...

Nov 16, 2026 · 2 min
Real Estate

Emirates REIT reports 12% rise in property income as Funds from Operations nearly double in Q3 2026

Emirates REIT (CEIC) PLC reported strong financial results for the nine months ended September 30, 2026, with year-on-year growth in property income, operating profit and Funds from Operations (FFO), alongside improvements in its balance sheet. Equitativa (Dubai) Limited, the manager of Emirates...

Nov 16, 2026 · 2 min
Education

Almasar Alshamil Education outlines vision for future of learning at Education Investment MENA 2026

Almasar Alshamil Education Chief Executive Officer Majed Al Mutairi joined regional education leaders at Education Investment MENA 2026 in Dubai, where discussions focused on the future of learning, the role of technology and the importance of collaboration across the education sector. Held on...

Nov 16, 2026 · 2 min
Trusted by

Our Associates

Brands and organisations that work with Day of Dubai.